Semapimod Sensitizes Glioblastoma Tumors to Ionizing Radiation by Targeting MicrogliaReportar como inadecuado

Semapimod Sensitizes Glioblastoma Tumors to Ionizing Radiation by Targeting Microglia - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Glioblastoma is the most malignant and lethal form of astrocytoma, with patients having a median survival time of approximately 15 months with current therapeutic modalities. It is therefore important to identify novel therapeutics. There is mounting evidence that microglia specialized brain-resident macrophages play a significant role in the development and progression of glioblastoma tumors. In this paper we show that microglia, in addition to stimulating glioblastoma cell invasion, also promote glioblastoma cell proliferation and resistance to ionizing radiation in vitro. We found that semapimod, a drug that selectively interferes with the function of macrophages and microglia, potently inhibits microglia-stimulated GL261 invasion, without affecting serum-stimulated glioblastoma cell invasion. Semapimod also inhibits microglia-stimulated resistance of glioblastoma cells to radiation, but has no significant effect on microglia-stimulated glioblastoma cell proliferation. We also found that intracranially administered semapimod strongly increases the survival of GL261 tumor-bearing animals in combination with radiation, but has no significant benefit in the absence of radiation. In conclusion, our observations indicate that semapimod sensitizes glioblastoma tumors to ionizing radiation by targeting microglia and-or infiltrating macrophages.

Autor: Ian S. Miller, Sebastien Didier, David W. Murray, Tia H. Turner, Magimairajan Issaivanan, Rosamaria Ruggieri, Yousef Al-Abed, Mar



Documentos relacionados